Latest news with #BCC
Time of India
4 days ago
- General
- Time of India
In a first, 17 women cadets to graduate from NDA alongside 300 male soldiers on May 30
Pune: NDA's first batch of female cadets at National Defence Academy in Pune. 17 female cadets are set to graduate alongside more than 300 male counterparts from the academy. On May 30th, history will be made at the National Defence Academy as the first 17 women cadets graduate alongside their male counterparts. This landmark event marks a significant step towards gender integration in India's armed forces, fulfilling a Supreme Court directive from 2022. Tired of too many ads? Remove Ads 'A complete transformation' Tired of too many ads? Remove Ads Breaking barriers, shaping futures Tired of too many ads? Remove Ads On May 30, Cadet Ishita Sharma will step onto the National Defence Academy NDA ) parade ground in Pune, not just as a graduate but as part of a moment that will go down in is among the first 17 women cadets who will pass out of the prestigious military institution — a landmark event in the journey of gender integration in India's armed 17 women, alongside nearly 300 male cadets, are set to become NDA's first co-ed graduating batch since the academy opened its doors to female aspirants in decades, the NDA had remained an all-male bastion. That changed following a Supreme Court directive, and now, three years later, the results of that shift are ready to be commissioned into military life.'I come from a non-military background. My parents work in the corporate sector, and my brother is an IT professional. I was pursuing a bachelor's degree in economics when NDA announced its entry for women. I didn't think twice before applying,' Ishita, who now holds the honorary title of Division Cadet Captain (DCC), told on her time at the academy, she said, 'After spending three years here, I can confidently say that my personality underwent a complete transformation.'For Ishita, leadership was not just taught, it was lived — with responsibilities like being DCC offering a chance to develop character and command from within the experience is echoed across the batch, with cadets describing the three years as intense, transformative, and deeply personal. 'Before joining the academy, I was an introvert. Here, I made several friends for life. In fact, my course mates feel like family now,' she cadet, Shriti Daksh, daughter of a retired wing commander, shared how the NDA experience not only matched but exceeded her expectations. 'At the academy, I actually understood what the real experience of military training feels like,' she first day at NDA was more than a moment of pride — it was a generational milestone. 'It was a special day for my father and me when he dropped me off at the academy, a mix of nostalgia and pride for him. Now, I am just a few days away from the moment my father experienced in his life, and I am excited to share that moment with him on May 30,' she Ritul Duhan, who became the first woman to be appointed Battalion Cadet Captain (BCC), knows the weight her position carries.'We're not just completing training; we are paving the way for future leadership and inspiring younger cadets,' she the physically and mentally demanding training, the women cadets said the environment was one of equal opportunity. 'Equal opportunity naturally empowers each individual. That is what makes the academy unique in all aspects,' Ishita time at NDA was defined not just by military drills and academic learning, but by breaking mental barriers. 'Once you break that mental barrier, you push your limits to the next level each time,' Ishita historic passing-out parade on May 30 will not only celebrate the graduation of these cadets, but also reflect a new chapter for the armed forces — one that signals inclusivity, resilience, and a future where leadership wears no gender.
NDTV
5 days ago
- Health
- NDTV
Harvard-Trained Dermatologist Warns: Early Signs Of Skin Cancer You Must Watch For
Skin cancers are the most common type of cancer around the world, with millions of cases each year. In 2022, the World Health Organisation reported about 330,000 new cases of melanoma, a serious type of skin cancer, and nearly 60,000 people died from it. Melanoma rates vary a lot in different countries, and men are more often affected than women in most places. A skin doctor trained at Harvard warns that some spots or blemishes on the skin, which may look harmless, could actually be cancer. Dr Daniel Sugai urges patients with persistent pimples that last longer than a month to seek treatment. "If you have a pimple that won't go away in four weeks, please see your dermatologist," he said this week on TikTok. Another sign it's time to get checked? Spots that bleed. "Another complaint I hear patients say is that, 'I just washed my face, and there's this one spot that keeps bleeding, and it does this bleed-scab cycle,' " said Sugai, who is based in the Seattle area. "If you have a spot that's not fully healing or is very fragile with gentle trauma, like washing your face, definitely see your dermatologist." According to The New York Post, Sugai shared that both symptoms could be signs of basal cell carcinoma (BCC), the most common type of cancer. Some 3.6 million Americans are diagnosed with BCC each year, according to the Skin Cancer Foundation. As the name implies, this skin cancer starts in basal cells, which produce new skin cells as the old ones die off, according to the Mayo Clinic. "I diagnose these every day, and I actually treat them surgically every day," said Sugai. BCCs develop "tree-like blood vessels" to aid their growth, making them especially prone to bleeding. BCC can manifest as a pimple that doesn't appear to heal, a shiny, skin-coloured bump, a white or waxy lesion, a flat, scaly patch or a lesion that is black, brown or blue. Addressing patients of colour, Sugai noted that BCC commonly presents as pigmented. "It's usually hyperpigmented with some red mixed in, and with time, it will start to be an eroded plaque that will bleed easily," he said. It's very important not to ignore any unusual changes or marks on your skin. Early detection can save lives.
New York Post
5 days ago
- Health
- New York Post
I'm a dermatologist — these easily overlooked signs on your skin may indicate cancer
Let's face it — your pimple may be more problematic than you realize. A Harvard-trained dermatologist warns that some benign-seeming blemishes could be cancerous. Dr. Daniel Sugai urges patients with persistent pimples that last longer than a month to seek treatment. 'If you have a pimple that won't go away in four weeks, please see your dermatologist,' he said this week on TikTok. 3 Dr. Daniel Sugai urges patients with persistent pimples that last longer than a month to seek treatment. – Another sign it's time to get checked? Spots that bleed. 'Another complaint I hear patients say is that, 'I just washed my face and there's this one spot that keeps bleeding and it does this bleed-scab cycle,' ' said Sugai, who is based in the Seattle area. 'If you have a spot that's not fully healing or is very fragile with gentle trauma, like washing your face, definitely see your dermatologist.' Sugai shared that both symptoms could be signs of basal cell carcinoma (BCC), the most common type of cancer. Some 3.6 million Americans are diagnosed with BCC each year, according to the Skin Cancer Foundation. As the name implies, this skin cancer starts in basal cells, which produce new skin cells as the old ones die off, according to the Mayo Clinic. 'I diagnose these every day, and I actually treat them surgically every day,' said Sugai. BCCs develop 'tree-like blood vessels' to aid their growth, making them especially prone to bleeding. BCC can manifest as a pimple that doesn't appear to heal, a shiny, skin-colored bump, a white or waxy lesion, a flat, scaly patch or a lesion that is black, brown or blue. Addressing patients of color, Sugai noted that BCC commonly presents as pigmented. 'It's usually hyperpigmented with some red mixed in, and with time, it will start to be an eroded plaque that will bleed easily,' he said. According to Sugai, the first two decades of life are absolutely critical for sun protection. 'Getting those sunburns early on in life will definitely affect how healthy your DNA is later on in life.' 3 Basal cell carcinomas develop 'tree-like blood vessels' to aid their growth, making them especially prone to bleeding. TikTok / @drspf Still, he said, late is better than never when it comes to preventative measures. 'If you're starting late in the sunscreen game, it's never too late,' Sugai advised. 'Keep wearing your sunscreen because we don't wanna overwhelm our skin with DNA mutations that are induced from the sun.' Like other types of skin cancer, BCCs can develop later in life, after years of sun exposure, and the treatment typically involves cutting the affected area out of the skin entirely. It's common to see this type of cancer pop up where the sun hits your skin — neck, arms, face and head — but that doesn't mean other parts of your body can't get it. 3 Some 3.6 million Americans are diagnosed with basal cell carcinoma each year, according to the Skin Cancer Foundation. TikTok / @drspf 'You can also get skin cancer where the sun doesn't shine — yes, like around your vulva or penis,' Dr. Fatima Fahs, a board-certified dermatologist and skin care expert based in Michigan, previously told The Post. 'Even though it might sound embarrassing, if there's a new 'pimple' or sore that won't heal, it's worth going to see a doctor.' What's more, Fahs added, your hands and nails aren't exempt either. 'New dark streaks or growths in and around the nails should always be evaluated, too,' she said. 'Melanoma of the nail bed is possible and can be more deadly.' Experts like Sugai and Fahs recommend that people be screened for skin cancer annually, or more often if they are at higher risk.
Malay Mail
7 days ago
- Business
- Malay Mail
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates Department of Health to Commence Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin
The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE [email protected] [email protected] Cautionary Notice on Forward-Looking Statements Philadelphia, Pennsylvania - Newsfile Corp. - May 22, 2025 - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has received study may proceed approval from the UAE DOH to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 36 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability study (SKNJCT-001) completed in March met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of Company also has SKNJCT-003 Phase 2 clinical study currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The company also announced expanding clinical trial sites in April 2025, the company also announced entering into a binding letter of intent to acquire Antev Ltd. (""), a UK-based late clinical stage biotech company, developinga next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged Bonner, President(610) 636-0184Anna Baran-Djokovic, SVP Investor Relations(305) 615-9162Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in April 2025, the company also announced entering into a binding letter of intent to acquire Antev Ltd. (""), a UK-based late clinical stage biotech company, developinga next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. The issuer is solely responsible for the content of this announcement.
Medscape
21-05-2025
- Health
- Medscape
Skin Cancer Burden Highest in Older Men, Rich Countries
In 2021, skin cancer affected millions of older adults globally. Basal cell carcinoma (BCC) had the highest incidence, while squamous cell carcinoma (SCC) accounted for the greatest disability burden, and men and high sociodemographic index (SDI) countries, especially in Australasia and North America, bore a disproportionate share of cases and deaths. METHODOLOGY: Researchers analyzed data from the Global Burden of Disease Study 2021 database covering 204 countries from 1990 to 2021. The analysis included age-standardized rates (ASRs) of prevalence, incidence, deaths, and disability-adjusted life years (DALYs) per 100,000 population associated with skin cancer among adults aged 65 years or older. Disease burden was stratified by sex, age, year, and SDI. TAKEAWAY: In 2021, there were an estimated 153,993 new cases of melanoma, 1,463,424 of SCC, and 2,802,354 of BCC. BCC had the highest incidence rate (ASRs, 371.97), whereas SCC exhibited the highest prevalence (ASR, 236.91) and DALYs (ASR, 95.50). Men had a higher incidence than women, and population growth was the major driver of the increasing disease burden. The highest ASRs of melanoma incidence (158.10), prevalence (1165.26), deaths (27.83), and DALYs (502.22) were reported in Australasia. North America had the highest incidence and prevalence rates for keratinocyte carcinoma (KC). Australasia also recorded the highest SCC-related deaths (ASR, 15.37) and DALYs (ASR, 226.92). The highest BCC-related DALY rate (ASR, 1.21) was observed in North America. Melanoma-related death rates were more than five times higher in high SDI countries (ASR, 9.49) than in low-middle to middle SDI countries. Despite high SDI levels, the United States, Greenland, Sweden, and Switzerland had disproportionately high BCC-related DALY rates, while New Zealand, Australia, Norway, North Macedonia, and Slovenia had higher-than-expected melanoma-related DALY rates. IN PRACTICE: 'The findings of this study suggest that the global disease burden of skin cancer in adults 65 years or older is on the rise, particularly among male individuals and in countries with a high SDI level,' the study authors wrote. 'Our results underscore the urgency to enact prevention and treatment strategies tailored to high-risk older populations.' SOURCE: This study was led by Ruiyao Wang, MD, Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University in Chongqing, China, and was published online on May 21 in JAMA Dermatology . LIMITATIONS: Limitations included underreporting of KC in major cancer registries, reliance on modeled estimates for countries with limited data, and the absence of race and ethnicity data. DISCLOSURES: This study received support from the National Natural Science Foundation of China and Chongqing Science and Technology Commission. The authors did not report any conflicts of interest.
